Tiny Arginine-Rich Peptides That Block Tumor Blood Supply and Slow Cancer Spread
Six-amino-acid peptides rich in arginine blocked VEGF signaling and inhibited both tumor growth and metastasis in animal models.
Quick Facts
What This Study Found
Arginine-rich hexapeptides identified from peptide libraries blocked VEGF from binding to its receptor (IC50 = 2–4 micromolar) and selectively inhibited VEGF-driven blood vessel growth without toxicity to normal cells.
In animal models, the peptides stopped new blood vessel formation in both chick membrane and rabbit cornea assays. Most notably, one hexapeptide (RRKRRR) blocked both the growth and spread of human colon cancer cells implanted in mice.
Key Numbers
IC50 = 2–4 µM for VEGF receptor binding inhibition · hexapeptide length (6 amino acids) · blocked VEGF165 and VEGF121 binding · inhibited HM7 colon carcinoma growth and metastasis in nude mice
How They Did This
The researchers screened peptide libraries to find short sequences that block VEGF from attaching to its receptor. They tested the best candidates in lab dishes (endothelial cell proliferation assays), then in live animal models — chick embryo membranes, rabbit corneas, and mice implanted with human colon cancer cells.
Why This Research Matters
Tumors need new blood vessels to grow and spread. VEGF is the main signal that triggers this process, making it one of the most important targets in cancer therapy. These tiny six-amino-acid peptides represent a fundamentally different approach to blocking VEGF — smaller, simpler, and potentially cheaper to produce than antibody-based drugs like bevacizumab (Avastin). If further developed, they could offer new treatment options for cancers and other diseases driven by abnormal blood vessel growth.
The Bigger Picture
Anti-VEGF therapy became one of the biggest stories in cancer treatment — drugs like Avastin (bevacizumab) generate billions in revenue by blocking the same pathway. This 2000 study represents an early attempt to achieve the same effect with much smaller, simpler molecules. While these specific peptides didn't advance to clinical use, the concept of peptide-based angiogenesis inhibitors remains active in drug development, offering potential advantages in cost, manufacturing, and tissue penetration over large antibody drugs.
What This Study Doesn't Tell Us
This is a preclinical study from 2000 — all results are from cell cultures and animal models, not human patients. The peptides' stability, dosing, and side effects in humans are unknown. No follow-up clinical trials have been reported.
Questions This Raises
- ?Can these arginine-rich hexapeptides be modified for better stability and potency in human-relevant conditions?
- ?How do these peptide-based VEGF blockers compare to antibody-based anti-VEGF drugs in terms of tumor penetration?
- ?Could similar peptides be effective against cancers that develop resistance to existing anti-VEGF therapies?
Trust & Context
- Key Stat:
- IC50 = 2–4 µM The concentration at which these tiny six-amino-acid peptides blocked half of VEGF receptor binding — demonstrating meaningful potency for such small molecules.
- Evidence Grade:
- Moderate evidence: the study demonstrates clear biological activity across multiple in vitro and in vivo models, but all results are preclinical with no human data. The findings were published in a high-quality journal (Journal of Biological Chemistry) with rigorous methodology.
- Study Age:
- Published in 2000, this is a foundational preclinical study. While the specific peptides weren't clinically developed, anti-VEGF therapy became a cornerstone of cancer treatment, validating the underlying approach.
- Original Title:
- Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.
- Published In:
- The Journal of biological chemistry, 275(18), 13588-96 (2000)
- Database ID:
- RPEP-00575
Evidence Hierarchy
Frequently Asked Questions
What are arginine-rich peptides and why do they block VEGF?
These are very short chains of amino acids (just six long) with a high proportion of arginine, a positively charged amino acid. They physically bind to VEGF — the protein tumors use to grow new blood vessels — and prevent it from attaching to its receptor, effectively cutting off the tumor's blood supply signal.
Could these peptides ever be used to treat cancer in people?
While these specific peptides haven't reached human trials, the concept they demonstrate — using small peptides to block tumor blood vessel growth — remains an active area of cancer drug development. The challenge is making such small molecules stable enough to work reliably in the human body.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00575APA
Bae, D G; Gho, Y S; Yoon, W H; Chae, C B. (2000). Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.. The Journal of biological chemistry, 275(18), 13588-96.
MLA
Bae, D G, et al. "Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.." The Journal of biological chemistry, 2000.
RethinkPeptides
RethinkPeptides Research Database. "Arginine-rich anti-vascular endothelial growth factor peptid..." RPEP-00575. Retrieved from https://rethinkpeptides.com/research/bae-2000-argininerich-antivascular-endothelial-growth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.